BioCentury
ARTICLE | Clinical News

Macritonin oral salmon calcitonin data

May 19, 1997 7:00 AM UTC

DLVRY announced that a Phase II/III trial has yielded positive findings at the three month end point, with 400 iu and 800 iu doses. In 212 women with osteoporosis as assessed by bone mineral density, combined data from the two doses showed a statistically significant reduction in the excretion of CrossLaps in the urine compared to placebo. The control group received vitamin D and calcium.

CrossLaps is a group of metabolic indicators of bone mineral density that has been correlated to risk of fractures. Nasal calcitonin was used as another, positive control in the trial and, as expected, also produced significant reduction in CrossLaps. The CrossLaps test is marketed by Osteometer (Ballerup, Denmark). ...